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Abstract
Background: The only US guidelines listed in the National Guideline Warehouse for the diagnosis
of Irritable Bowel Syndrome (IBS) are the expert opinion guidelines published by The American
Gastroenterology Association. Although the listed target audience of these guidelines includes
family physicians and general internists, the care recommended in the guidelines has not been
compared to actual primary care practice. This study was designed to compare expert opinion
guidelines with the actual primary care provided and to assess outcomes in the 3 years following
the IBS diagnosis.
Methods: This is a retrospective medical record review study using a random sample of incident
IBS cases from all Olmsted County, Minnesota providers diagnosed between January 1, 1993 and
December 31, 1995. Data was collected on all care and testing provided to the subjects as well as
3-year outcomes related to the IBS diagnosis.
Results: Of the 149 IBS patients, 99 were women and the mean age was 47.6 years. No patient
had all of the diagnostic tests recommended in the guidelines. 42% had the basic blood tests of CBC
and a chemistry panel. Sedimentation rate (2%) and serum thyroxine level (3%) were uncommon.
Colon imaging studies were done in 41% including 74% of those over the age of 50. In the 3 years
following the diagnosis, only one person had a change in diagnosis and no diagnoses of gastro-
intestinal malignancies were made in the cohort.
Conclusions: Primary care practice based diagnostic evaluations for IBS differ significantly from
the specialty expert opinion-based guidelines. Implementation of the specialty guidelines in primary
care practice would increase utilization with apparent limited improvement in diagnostic outcomes.
Background
Irritable bowel syndrome is a gastro-intestinal (GI) dis-
order of unknown etiology often described as a function-
al bowel problem. [1–3] The diagnosis of IBS rests on the
occurrence of a set of symptoms and the exclusion of oth-
er GI pathology. [4–7] The only published US guidelines
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for evaluation of patients with possible IBS have been de-
veloped by the American Gastroenterological Associa-
tion (AGA).[3] Due to the lack of higher levels of
evidence, the guidelines are based on expert opinion and
are likely to reflect the clinical experience of these spe-
cialists with the small percent (6 to 8%)[8] of all IBS pa-
tients seen by gastroenterologists in the US. [9] Little has
been written about the potential implications of imple-
menting the only currently available IBS diagnostic
guidelines[10] or how the guidelines compare to existing
community practice.
Using a community population-based sample of subjects
with an incident diagnosis of IBS, we reviewed the GI-re-
lated health care utilization and diagnostic evaluations
completed around the time of first (incident) IBS diagno-
sis and compared those evaluations to the AGA guide-
lines for the diagnosis of IBS. In addition, we evaluated
the utilization implications of implementing the AGA
guidelines in this patient population. The purpose of the
study is not to validate the guidelines but to see how they
compare to current primary care practice and to under-




Olmsted County is a metropolitan statistical area (MSA)
of 135,000 people 90 miles south of Minneapolis, Min-
nesota. The population is estimated to be 92 percent
white non-Hispanic. [11] Olmsted County has local re-
sources for primary, and specialty care. Previous studies
estimate that over 98 percent of all Olmsted County res-
idents' health care is delivered within Olmsted County
[11] by the Mayo Medical Center (MMC), the Olmsted
Medical Center (OMC) or the single solo practice family
physician's office in Rochester.
Data Collection
The cohort was identified using the database of the Ro-
chester Epidemiology Project (REP)[11,12] that collects
all diagnoses made within all Olmsted County medical
facilities and links all people in Olmsted County to all
sources of health care they use. All people with a diagno-
sis of functional or irritable bowel syndrome (564.1) or
spastic colon – psychogenic (306.4) during 1993–1995
were identified from the database. Broad criteria were
used for the search to increase sensitivity at the risk of re-
ducing specificity. This type of search strategy was possi-
ble since final subject selection relied on medical record
review rather than only administrative data. [13] The in-
itial search identified 1245 potential cases (a combina-
tion of incident and prevalent cases) of which 36 (2.9%)
had previously refused general record review research
authorization and thus could not be included in the study
according to Minnesota statute.[14] The goal was to
identify 150 subjects for in-depth review using data from
all sources of medical care each individual has used with-
in the county. The sample size was selected based on the
desire to have a sufficient sample to provide estimates of
compliance with individual elements of the guidelines
with confidence intervals of +/- 5% for those tests with
very high and very low compliance and +/-8% for those
near 50% compliance. This is a descriptive study and
therefore no other types of sample size calculations were
made.
The 1245 people identified by the initial search of the
REP database, were put into a random order and the
medical records of potential subjects' were screened un-
til the final cohort of 150 patients who met the inclusion
criteria were identified. A total of 416 potential IBS sub-
jects were screened to identify the final incident cohort of
150 subjects who had lived in Olmsted County for at least
3 years and had no previous diagnoses of IBS listed in
any medical records in the county. The minimum of 3
years of residency within Olmsted County was used to
improve the likelihood that review of the complete avail-
able medical records would identify prevalent rather
than incident cases of IBS. The assurance that patients
represented an incident diagnosis of IBS was especially
important in this study comparing diagnostic evalua-
tions completed to the recommended guidelines for ini-
tial evaluation. Potential subjects from the group of 416
were excluded during screening primarily for 1 of 3 rea-
sons: they were prevalent rather than incident cases of
IBS (n = 67), no actual diagnosis of IBS was documented
in any of the subject's medical records (n = 41) or they
had been an Olmsted County resident for < 3 years (n =
93). Another 65 people had a group of miscellaneous rea-
sons for exclusion including incident diagnosis date out-
side the window of this study, age < 16 at diagnosis, and
missing records.
All medical records of the 150 subjects in the final cohort
(those meeting the eligibility criteria) were reviewed in
detail to abstract data on demographic characteristics,
visits for gastro-intestinal or abdominal problems, and
non-GI symptom-related visits from 10 years before the
first IBS diagnosis to 3 years after. GI symptom-related
visits were those in which any symptom, sign or com-
plaint referable to the GI tract was recorded. This includ-
ed such complaints as diarrhea, abdominal pain,
constipation, change in stool habits, and vomiting. All
other visits were considered non-GI related. Information
on the presenting complaint, specialty of physician seen,
tests ordered and site of the visit (emergency depart-
ment, office, or hospital) was recorded. Data collection
began at the earliest visit that occurred 10 years or less
before the incident IBS diagnosis. Long term data wereBMC Gastroenterology 2001, 1:11 http://www.biomedcentral.com/1471-230X/1/11
available for most patients (mean = 7.3 years, median 7
years) and were used to assure that there was no previ-
ous diagnosis of IBS. The data of most interest for this
comparison of diagnostic evaluations completed and the
testing recommended in the guidelines were visits in 2
years before the diagnosis of IBS. Diagnostic outcomes
were assessed during the 3 years after the incident diag-
nosis. These data were present in 100% of subjects.
Data analysis
One subject revoked general research authorization (re-
quired by Minnesota statute) during data analysis and
thus the analysis was completed for the remaining 149
subjects. Descriptive information is presented as sum-
mary statistics.
Health care utilization was stratified into 2 major time
periods: a) the 60 days surrounding the incident IBS di-
agnosis (30 days before to 30 days after) called the im-
mediate diagnostic period; and b) the 2 years prior to the
diagnosis, excluding the 30 days before termed the ex-
tended diagnostic period. For referral to a GI specialist
we also included the 1 year after the diagnosis since refer-
ral for non-urgent conditions may take a considerable
period of time. The designation of the 60-day "diagnostic
period" was based on the clinical judgement of the au-
thors and was felt to reflect the usual time required to
complete a diagnostic evaluation. The percent of subjects
using each of the recommended services was calculated
for the diagnostic period and then for the extended im-
mediate diagnostic period (included the 2 year period
prior to the incident diagnosis). The extended window of
time was important for such tests as colonoscopy that
may not be repeated within 2 years of a normal examina-
tion.
Comparisons of test utilization between age groups, gen-
ders and those who did and did not have a gastroenterol-
ogist involved in their care were made using the
Wilcoxon rank-sum test. Chi-square tests were used to
compare frequencies of events.
The potential impact of fully implementing the AGA
guidelines (Table 1) was assessed. The additional tests
that would be needed for full implementation was calcu-
lated by subtracting the tests provided in this study from
tests that would need to be completed if all subjects' eval-
uations met the guidelines. Diagnostic outcomes (e.g.
changes in diagnoses from IBS to another GI disease in
the 3 years following first IBS diagnosis) is reported as a
single percent of total diagnosis.
This study was approved by the Olmsted Medical Center
and the Mayo Medical Center Institutional Review
Boards. The funding agency had no role in study design
or right of approval of manuscripts submitted for publi-
cation. The author who worked for the funding agency
was one of the epidemiologist members of the design
team and reviewed the final draft of the manuscript.
Results
Two thirds of the 149 subjects (n = 99) were women. The
mean age of the subjects at the time of diagnosis was 47.6
years (s.d. 17.8 years and range 16 to 91 years) and was
the same for men and women. Most of the IBS diagnoses
(94%) were made by family physicians and general in-
ternists with 13% of subjects seeing a gastroenterologist
at any time in the period 2 years before to 1 year after the
diagnosis.
Table 2 summarizes the percent of people having each
test or group of tests that are recommended for diagnos-
tic evaluation by the AGA guidelines. In this cohort, test-
ing did not vary significantly by sex. Only the completion
of some type of colon imaging (flexible sigmoidoscopy,
colonoscopy or barium enema) varied by age with 74% (n
= 46) of those 50 and older at diagnosis versus 38% (n =
33) of those younger than 50 at diagnosis having one of
the tests documented. Since the guidelines were devel-
oped by a panel of gastroenterologists, the compliance
with the guidelines in those subjects seeing a GI special-
ist was also calculated (n = 19). All types of colon imaging
were more common in those with GI specialty visits [79%
(n = 15) versus 50% (n = 64), p > 0.05] but only the in-
crease in flexible sigmoidoscopies reached statistical sig-
nificance [53%, (n = 10) versus 19%, (n = 25), p < 0.05].
The only other diagnostic tests that were statistically
more likely to be completed in those seen by a gastroen-
terologist were stool testing for ova and parasites [53%,
Table 1: Diagnostic evaluation recommended based on US Amer-
ican Gastroenterological Association guidelines.





Stool for O & P
Stool for occult blood
Flexible sigmoidoscopy
IF > 50, colonoscopy or barium enema and sigmoidoscopy
For diarrhea predominant:
Small bowel radiograph




Plain film of abdomenBMC Gastroenterology 2001, 1:11 http://www.biomedcentral.com/1471-230X/1/11
(n = 10) versus 16%, (n = 21), p < 0.05] and fecal occult
blood [26%, (n = 5) versus 9% (n = 12), p < 0.05].
The final column of Table 2 reflects the additional
number of people (and percent of the subjects) who
would require each category of test to comply with the
AGA guidelines [3] for diagnosis of IBS.
In those subjects with primarily diarrhea (n = 82), the
guidelines suggest a small bowel radiograph and a lac-
tose/dextrose H2 breath test. Twelve subjects (15%) had
a small bowel radiograph and none had H2 breath test-
ing. For those with abdominal pain (n = 110) the guide-
lines recommend a plain film of the abdomen. Thirteen
of these patients (12%) had a flat plate.
In the three years after the diagnosis of IBS, only one
subject had any change in diagnosis from IBS to another
condition related to the symptoms. This 23-year old sub-
ject was diagnosed with inflammatory bowel disease ap-
proximately one year after the initial IBS diagnosis. No
subject was diagnosed with any type of GI-related malig-
nancy and there were no deaths in the cohort.
Discussion
The evaluation of IBS in this community population-
based cohort of primary care patients differed signifi-
cantly from that recommended by the AGA guidelines
[3] for IBS evaluation. The evaluation of GI-related signs
and symptoms appeared to be based primarily on history
and physical examination with minimal specific testing
or imaging of the GI tract. The inclusion of a GI specialist
in the subject's care increased but did not guarantee
compliance with the AGA guidelines.
The diagnostic guidelines developed and published by
the AGA are available in several formats including as
part of the guideline warehouse sponsored by the Agency
for Health Care Research and Quality (AHRQ)
[www.guidelines.gov/ibs]  where they are listed as appli-
cable to family medicine, internal medicine, gastroenter-
ology and primary care. Physicians who are familiar with
the medical literature will know that almost all elements
of the IBS guideline required expert opinion since little
other evidence was available. Unfortunately, the level of
evidence used is not clearly stated. [15] Furthermore, the
AGA guidelines were developed by a panel limited to gas-
troenterologist physicians. However, gastroenterologists
see only a minority of IBS patients.[8] Over 94% of the
subjects in this sample were initially evaluated by family
physicians and general internists with only 13% ever see-
ing a gastroenterologist in the 7 years before or 3 years
after the incident IBS diagnosis. Therefore, subspecialty
developed guidelines may not be appropriate for the ma-
jority of IBS care especially when the guidelines have to
be based primarily on opinion which likely reflects only
the experience of physicians included in the guideline
development panel.
The complete printed position statement that accompa-
nies the original publication of the AGA guidelines does
note the potential lack of applicability to primary care
patients (> 85% of all IBS patients) stating "...Primary
care patients may be different and may be followed with
expectant management". [3] However, expectant man-
agement is not specified nor are the specific indications
for referral to a specialist presented. The position paper
also recognizes that "...there is a risk of overdoing the di-
agnostic evaluation to rule out organic disease". Within
the guideline warehouse  [www.guidelines.gov]  these
Table 2: Diagnostic testing proximate to the incident IBS diagnosis
Test Diagnosis Period -2yr to + 30 day Additional number of
n (%) n (%) subjects (%) needing to
complete testing to comply
with IBS evaluation guidelines
N = 149 (%)
CBC 53 (36) 68 (46) 96 (64)
Chemistry panel 50 (34) 64 (43) 99 (66)
Sedimentation Rate 3 (2) 5 (3.3) 146 (98)
Stool for O & P 26 (17) 31 (21) 123 (83)
Stool for Occult blood 16 (11) 17 (11) 133 (89)
Flexible sigmoidoscopy 25 (17) 10 (7) 112 (76)
Colon imaging+ 61 (41) 79 (53) 70 (47)
Referral to GI specialist 6 (4) 13 (9) NA
+ colonoscopy, barium enema or flexible sigmoidoscopy (to allow greater inclusiveness by adding alternatives to flexible sigmoidoscopy)BMC Gastroenterology 2001, 1:11 http://www.biomedcentral.com/1471-230X/1/11
modifiers are missing. No data are presented in any for-
mat that provide any rationale for extending the AGA
guidelines to primary care practice.
The additional testing that would be required to meet the
AGA guidelines [3] is extensive (Table 2) and would like-
ly result in significant increases in health care expendi-
tures. Even if the guidelines were applied only to those
visiting a gastroenterologist (assumed to be 13% of sub-
jects in our study), additional health care utilization
would be required. The anticipated gain in improved di-
agnostic accuracy appears to be limited since in this co-
hort only one diagnosis was changed from IBS in the 3
years of follow up after the incident IBS diagnosis.
The value of completing all of the additional testing rec-
ommended by the guidelines cannot be completely as-
sessed with this data set. However, the outcome of no
new GI malignancies in the three years of follow up of
this cohort is comparable to other studies of prognosis in
IBS [16] and suggests additional testing would be of lim-
ited value in identifying life threatening conditions. The
value of the additional testing or referrals on the pa-
tient's quality of life or other health conditions is not
known and requires additional research. The format of
that additional research might be similar to the studies
for other guidelines such as the study of the cost implica-
tions of implementing guidelines that recommend radio-
graphs for evaluation of low back pain. [17] Such a study
for IBS guidelines would need to assess the added value
of the extensive work-up recommended by the specialty
guidelines in a larger population over a longer period of
time and could be compared to the outcomes (including
patient satisfaction) of a group assigned to more limited
evaluation as completed in this study. It would be impor-
tant to determine if the additional tests or referrals
would identify other diseases, serve to more fully reas-
sure the patient or simply have become what patients
and specialist expect to occur with a GI specialty visit.
[18]
Failure to comply with one aspect of the guidelines is
worth specific mention. While subjects over age 50 were
more likely to have colon-imaging studies, 25% of them
had no colon imaging studies or assessment of fecal oc-
cult blood. This is not consistent with the published evi-
dence based U.S. Preventive Services Task Force
(USPSTF) guidelines for routine screening and preven-
tive care related to colon cancer for asymptomatic peo-
ple 50 years and older and appear to represent missed
screening opportunities. [19,20] The addition of a GI
specialist in the patient's care increased but did not guar-
antee compliance with the USPSTF guidelines for
screening studies of the colon.
The AGA[3] had little evidence of any higher level than
expert opinion on which to base IBS guidelines. The dis-
parity between the testing family physicians and general
internists choose to evaluate potential IBS and that rec-
ommended in the guidelines highlights the potential im-
pact of using subspecialty experts to define
recommended care in a primary care condition with lim-
ited research based evidence. If indeed gastroenterolo-
gists do see a sicker or otherwise different group of
people with IBS than seen by family physicians and gen-
eral internists then more extensive evaluation by gastro-
enterologists would be appropriate to consider. If the GI
specialty patients are no more likely to have other diseas-
es but are just more likely to be dissatisfied with care and
need additional reassurance, more testing may not be the
most cost effective solution. Alternative considerations
such as group therapy, support groups or additional ed-
ucation may be a better use of resources and time. [21] In
this population, the disparity between the care given and
that recommended reinforces the value of understanding
the full spectrum of disease when developing opinion
based guidelines as well as the importance of developing
evidence based guidelines as opposed to expert opinion
based guidelines whenever possible.
This is a relatively small cohort of primary care patients
from a single county. Practices in other communities and
with patients of more diverse racial and ethnic back-
ground may be different. Medical records rarely reflect
every thing that happens during any medical encounter.
It is possible that additional testing did occur. However,
tests often involve people other than the physician, are
billable items in the non-capitated care environment we
studied and therefore significant amounts of undocu-
mented testing is unlikely. The use of medical records
did allow the date of the incident diagnosis to be pin-
pointed and allowed us to assess diagnostic evaluation in
temporal relation to the incident diagnosis making com-
parison with diagnostic guidelines possible. Our limited
sample size may not have been sufficient to allow accu-
rate assessment of missed GI malignancies.
Conclusion
Community based evaluation of IBS differs from the con-
sensus based guidelines developed by specialists. The
limited testing done in this population appeared to limit
health care expenditures without adversely impacting
the recognition of life threatening GI disease. To allow
physician assessment of the potential applicability of
published guidelines, the guidelines should always be ac-
companied by information regarding the target popula-
tion (i.e. primary care patients versus specialty care
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